Aker BioMarine Hires Two Top Scientists to Strengthen its R&D Initiatives
Aker BioMarine, a global biotech innovator and world-leading supplier of krill, announces two new talents on the Human Nutrition team. Katina Handeland, PhD., and Yunpeng Ding, PhD. have both joined Aker BioMarine as Directors for Research & Development (R&D). They will be responsible for research within the company’s human health and nutrition department.
“We are thrilled to add such top caliber scientists to our Human Health and Nutrition team,” says Tim de Haas, EVP for Human Nutrition at Aker BioMarine. “Each of them brings extensive knowledge and experience to the table, elevating our current research efforts as well as new areas for the future.”
Handeland will be working to both design and follow-up the pre-clinical and clinical trials for the human health portfolio, studying the biological effects of krill and its benefits.
“I am very excited to join the team and to play a part in contributing to better and healthier lives globally,” says Katina Handeland. “In addition to the work currently in progress, I will help support the establishment of potential new product lines and areas of focus.”
Katina Handeland holds a Ph.D. in Nutrition from the University of Bergen. She has extensive experience with innovation projects for medical nutrition, and she currently serves as the President of the Board for the Norwegian Nutrition Society.
Yunpeng Ding holds a Ph.D. in Epidemiology and Biostatistics from the University of Bergen. He has previously worked with drug development and early phase clinical trials, and he has most recently served as a senior statistician for a medical research company in Norway.
“My focus will be on Superba Krill oil and its potential for sports performance, metabolic syndrome, as well as cardiovascular and cognitive health,” says Ding. “Going forward, I foresee adding healthy aging and personalized nutrition to my research, as we expand our efforts to find sustainable solutions to improve public health.”
Handeland and Ding are based at the company headquarters in Lysaker, Norway.
About Aker BioMarine ASA
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Listed on Oslo Stock Exchange, the company develops krill-based ingredients for pharmaceutical, nutraceutical (Superba®), aquaculture (QRILL® Aqua), and animal feed applications (QRILL® Pet), including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill. Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste. Read more: www.akerbiomarine.com
Related news
-
Creative Proteomics: GutFlora Omics Platform Launches Virome Sequencing Service to Investigate Gut Microbiota
GutFlora Omics Platform belongs to Creative Proteomics. With more than 10 years of experience in providing advanced multi-omics services, the GutFlora Omics Platform offers services and support to customers through comprehensive intestinal flora research solutions. GutFlora Omics Platform recently announced the launch of virome sequencing service to better study gut microbiota. The gut microbiome includes a huge number of bacteria, archaea, fungi, and enteroviruses that colonize the gut. At present, most of the...
-
CD Genomics Fully Supports Your Microbiome Research with Comprehensive Sequencing Solutions
CD Genomics is a leading services company committed to providing global customers with the most comprehensive analytic services, including a broad range of microbial genomic solutions to support research and development. The company announced microbiome profiling services, alongside bioinformatic analysis technology to help researchers understand the significance of human and animal microbiota. Through long-term and detailed studies of the gut microbiota, scientists have revealed the complex relationship...
-
Raman Spectrometry-Based Metabolomic Analysis Service Now Available by the GutFlora Omics Platform
The GutFlora Omics Platform belongs to Creative Proteomics. With more than 10 years of experience in providing advanced multi-omics services, GutFlora Omics offers services and support to customers through comprehensive gut microbiota research solutions. Creative Proteomics released comprehensive Raman spectrometry-based metabolomic analysis service to assist with your gut microbiota metabolomics research. The microorganisms living in the human intestine form a complex community, which has a wide range of...
-
MicrobioSeq Releases Microecology and Biofilms Solutions for Your Research
MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable sequencing, genotyping, microarray, and bioinformatics services. The company has recently launched high-quality microecology and biofilms solutions to help explore the microbial diversity and structure of biofilm samples. Bacterial communities that adhere to surfaces are referred to as biofilms. They contribute to ecosystem...
-
MicrobioSeq`s Microbial Therapeutics: A New Opportunity for Medicine
MicrobioSeq represents the microbial genomics division of CD Genomics headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation in providing reliable de novo sequencing, genotyping, microarray, and bioinformatics services. With years of experience in the pharmaceutical and life science sector, CD Genomics has recently announced microbial therapeutics solutions for drug development. The bacterial communities on the human body surface and in the body are becoming an important...
Customer comments
No comments were found for Aker BioMarine Hires Two Top Scientists to Strengthen its R&D Initiatives. Be the first to comment!